CA24463V1013
© EQS Newswire
06.06.2024
DTC
LISTED
CSE
DEFENCE VERÖFFENTLICHT SEINE PEER-REVIEW-STUDIE MIT PRÄKLINISCHEN DATEN ÜBER ACCUTOX ALS ANTIKREBSMOLEKÜL IM RENOMMIERTEN ‚JOURNAL OF TRANSLATIONAL MEDICINE‘
News Preview
_________________________________________________________________
CSE: DTC Börse Frankfurt: DTC OTCQB: DTCFF PRESSEMITTEILUNG
DEFENCE VERÖFFENTLICHT SEINE PEER-REVIEW-STUDIE MIT PRÄKLINISCHEN DATEN ÜBER ACCUTOX ALS ANTIKREBSMOLEKÜL IM RENOMMIERTEN ‚JOURNAL OF TRANSLATIONAL MEDICINE‘
Vancouver, British Columbia, Kanada, den 6. Juni ......
Themefolio
Profiler
Peergroup
© Newsfile
06.06.2024
DTC
LISTED
CSE
Defence's AccuTOX Published in the Prestigious Journal of Translational Medicine Its Peer Study with Preclinical Data on AccuTOX as an Anti-Cancer Molecule
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to announce the publication of a peer-reviewed study on the anticancer...
Themefolio
Profiler
Peergroup
© EQS Newswire
06.06.2024
DTC
LISTED
CSE
DEFENCE’S ACCUTOX PUBLISHED IN THE PRESTIGIOUS JOURNAL OF TRANSLATIONAL MEDICINE ITS PEER STUDY WITH PRECLINICAL DATA ON ACCUTOX AS AN ANTI-CANCER MOLECULE
News Preview
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE’S ACCUTOX PUBLISHED IN THE PRESTIGIOUS JOURNAL OF TRANSLATIONAL MEDICINE ITS PEER STUDY WITH PRECLINICAL DATA ON ACCUTOX AS AN ANTI-CANCER MOLECULE
Vancouver, BC, Canada, June 6th, 2024 - Defence Therapeutics Inc. (......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© EQS Newswire
06.06.2024
DTC
LISTED
CSE
DEFENCE’S ACCUTOX PUBLISHED IN THE PRESTIGIOUS JOURNAL OF TRANSLATIONAL MEDICINE ITS PEER STUDY WITH PRECLINICAL DATA ON ACCUTOX AS AN ANTI-CANCER MOLECULE
News Preview
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE’S ACCUTOX PUBLISHED IN THE PRESTIGIOUS JOURNAL OF TRANSLATIONAL MEDICINE ITS PEER STUDY WITH PRECLINICAL DATA ON ACCUTOX AS AN ANTI-CANCER MOLECULE
Vancouver, BC, Canada, June 6th, 2024 - Defence Therapeutics Inc. (......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
14.05.2024
DTC
LISTED
CSE
Defence Therapeutics Strengthens and Expands Global Patent Protection on Key Technologies
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the issuance of several new patents, as well as new allowanc...
Themefolio
Profiler
Peergroup
© EQS Newswire
14.05.2024
DTC
LISTED
CSE
DEFENCE THERAPEUTICS VERSTÄRKT UND ERWEITERT DEN WELTWEITEN PATENTSCHUTZ FÜR SCHLÜSSELTECHNOLOGIEN
News Preview
CSE: DTC Börse Frankfurt: DTC USOTC:DTCFF PRESSEMITTEILUNG
DEFENCE THERAPEUTICS VERSTÄRKT UND ERWEITERT DEN WELTWEITEN PATENTSCHUTZ FÜR SCHLÜSSELTECHNOLOGIEN
Vancouver, British Columbia, Kanada, den 14. Mai 2024 - Defence Therapeutics Inc. („Defence“ oder das „Unternehmen“), (CSE: DTC, OTCQB: DTCFF, Börse Frankfurt: DTC), ein kanadische......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.05.2024
DTC
LISTED
CSE
DEFENCE THERAPEUTICS STRENGTHENS AND EXPANDS GLOBAL PATENT PROTECTION ON KEY TECHNOLOGIES
News Preview
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE THERAPEUTICS STRENGTHENS AND EXPANDS GLOBAL PATENT PROTECTION ON KEY TECHNOLOGIES
Vancouver, BC, Canada, May 14, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology ......
Themefolio
Profiler
Peergroup
© EQS Newswire
02.05.2024
DTC
LISTED
CSE
ERFOLGREICHER TEST ZUR BEKÄMPFUNG VON PANKREASKREBS MIT DEM ARM-002-IMPFSTOFF VON DEFENCE
News Preview
_________________________________________________________________
CSE: DTC Börse Frankfurt: DTC USOTC:DTCFF PRESSEMITTEILUNG
PANKREASKREBS: ERFOLGREICHER TEST ZUR BEKÄMPFUNG VON PANKREASKREBS MIT DEM ARM-002-IMPFSTOFF VON DEFENCE
Vancouver, British Columbia, Kanada, den 1. Mai 2024 - Defence Therapeutics Inc. („Defence“ oder das „Unter......
Themefolio
Profiler
Peergroup
© EQS Newswire
02.05.2024
DTC
LISTED
CSE
ERFOLGREICHER TEST ZUR BEKÄMPFUNG VON PANKREASKREBS MIT DEM ARM-002-IMPFSTOFF VON DEFENCE
News Preview
_________________________________________________________________
CSE: DTC Börse Frankfurt: DTC USOTC:DTCFF PRESSEMITTEILUNG
PANKREASKREBS: ERFOLGREICHER TEST ZUR BEKÄMPFUNG VON PANKREASKREBS MIT DEM ARM-002-IMPFSTOFF VON DEFENCE
Vancouver, British Columbia, Kanada, den 1. Mai 2024 - Defence Therapeutics Inc. („Defence“ oder das „Unter......
Themefolio
Profiler
Peergroup
© EQS Newswire
02.05.2024
DTC
LISTED
CSE
SUCCESFUL TRIAL AGAINST PANCREATIC CANCER WITH DEFENCE’S ARM-002 ANTI-CANCER VACCINE
News Preview
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
PANCREACTIC CANCER: SUCCESFUL TRIAL AGAINST PANCREATIC CANCER WITH DEFENCE’S ARM-002 ANTI-CANCER VACCINE
Vancouver, BC, Canada, May 1st, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: D......
Themefolio
Profiler
Peergroup
© Newsfile
01.05.2024
DTC
LISTED
CSE
Pancreatic Cancer: Successful Trial Against Pancreatic Cancer with Defence Therapeutics' ARM-002 Anti-Cancer Vaccine
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 1, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the successful completion of a pre-clinical vaccination...
Themefolio
Profiler
Peergroup
© EQS Newswire
23.04.2024
DTC
LISTED
CSE
DER ACCUTOX ARM-002-IMPFSTOFF ZUR KREBSBEKÄMPFUNG FÜHRT ZU EINER HOCHWIRKSAMEN ANTIGENPRÄSENTATION
News Preview
Vancouver, British Columbia, Kanada, den 23. April 2024 - Defence Therapeutics Inc. („Defence“ oder das „Unternehmen“), (CSE: DTC, OTCQB: DTCFF, Börse Frankfurt: DTC), ein kanadisches Biotech-Unternehmen, das neuartige immunonkologische Therapeutika und Technologien zur Arzneimittelverabreichung entwickelt, freut sich bekanntzugeben, dass sein ARMT......
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
23.04.2024
DTC
LISTED
CSE
Defence's AccuTOX Anti-Cancer ARM-002 Vaccine Exhibits Potent Antigen Presentation
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that its second-generation ARMTM anti-cancer vaccine u...
Themefolio
Profiler
Peergroup
© EQS Newswire
23.04.2024
DTC
LISTED
CSE
DEFENCE’S ACCUTOX ANTI-CANCER ARM-002 VACCINE EXHIBITS POTENT ANTIGEN PRESENTATION
News Preview
Vancouver, BC, Canada, April 23rd, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that its second-generation ARMTM anti-cancer vaccine using AccuTOX®, called AR......
Themefolio
Profiler
Peergroup
© Newsfile
17.04.2024
DTC
LISTED
CSE
Defence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline Growth
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that FMS Consult GmbH ("FMS"), a European corporate fi...
Themefolio
Profiler
Peergroup
© EQS Newswire
17.04.2024
DTC
LISTED
CSE
DEFENCE THERAPEUTICS SIGNS WITH GERMAN BASED FMS CONSULT GMBH FOR FINANCING STRATEGY TO SUPPORT DEFENCE PIPELINE GROWTH
News Preview
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
Vancouver, BC, Canada, April 17th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that FMS Consult GmbH (“F......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.04.2024
DTC
LISTED
CSE
DEFENCE THERAPEUTICS UNTERZEICHNET MIT DER DEUTSCHEN FMS CONSULT GMBH EINE FINANZIERUNGSSTRATEGIE ZUR UNTERSTÜTZUNG DES WACHSTUMS DES DEFENCE-PORTFOLIOS
News Preview
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
Vancouver, BC, Kanada, 17. April 2024 - Defence Therapeutics Inc. (“Defence” oder das („Unternehmen”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), ein kanadisches biopharmazeutisches Unternehmen, das neuartige Immunonkologie-Therapeutika und Arzneimittelabgabetechnologien entwickelt, freut sich bekannt z......
Themefolio
Profiler
Peergroup
© Newsfile
06.04.2024
DTC
LISTED
CSE
Defence Therapeutics Announces Warrant Terms Amendment
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 5, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology, announces an amendment to the terms of 1,497,780 Class A Common share purchase warrants (the "Warran...
Themefolio
Profiler
Peergroup
© EQS Newswire
26.03.2024
DTC
LISTED
CSE
ERFOLGE VON DEFENCE BEI SEINEM ACCUTOX®-ARM(TM)-VAKZIN ZUR KREBSBEKÄMPFUNG FÜHREN ZUR ENTWICKLUNG EINES WIRKUNGSVOLLEN ARM-002(TM)-KREBSIMPFSTOFFS DER ZWEITEN GENERATION
News Preview
CSE: DTC Börse Frankfurt: DTC OTCQB: DTCFF PRESSEMITTEILUNG
ERFOLGE VON DEFENCE BEI SEINEM ACCUTOX®-ARMTM-VAKZIN ZUR KREBSBEKÄMPFUNG FÜHREN ZUR ENTWICKLUNG EINES WIRKUNGSVOLLEN ARM-002TM-KREBSIMPFSTOFFS DER ZWEITEN GENERATION
Vancouver, British Columbia, Kanada, den 26. März 2024 – Defence Therapeutics Inc. („Defence“ oder das „Untern......
Themefolio
Profiler
Peergroup
© Newsfile
26.03.2024
DTC
LISTED
CSE
Defence's Successful Results on Its AccuTOX Anti-Cancer ARM Vaccine Creates a Potent Second-Generation Anti-Cancer ARM-002 Vaccine
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 26, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biotechnology company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the successful testing of a second-generation anti-cancer...
Themefolio
Profiler
Peergroup
© EQS Newswire
26.03.2024
DTC
LISTED
CSE
DEFENCE’S SUCCESSFUL RESULTS ON ITS ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE
News Preview
_________________________________________________________________
CSE: DTC FSE: DTC OTCQB: DTCFF PRESS RELEASE
DEFENCE’S SUCCESSFUL RESULTS ON ITS ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE
Vancouver, BC, Canada, March 26th, 2024 - Defence Therapeutics Inc. (“Defence” or ......
Themefolio
Profiler
Peergroup
© Newsfile
22.03.2024
DTC
LISTED
CSE
Defence Completes 2nd Tranche of Financing
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 22, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology, announces the closing of the 2nd tranche of its previously announced non-brokered private placemen...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.03.2024
DTC
LISTED
CSE
DEFENCE THERAPEUTICS WURDE EIN UMFASSENDES PATENT GEWÄHRT, DAS DIE BAHNBRECHENDE ACCUTOX®-TECHNOLOGIE ZUR KREBSBEKÄMPFUNG ABDECKT
News Preview
________________________________________________________________
CSE: DTC Börse Frankfurt: DTC USOTC: DTCFF PRESSEMITTEILUNG
DEFENCE THERAPEUTICS WURDE EIN UMFASSENDES PATENT GEWÄHRT, DAS DIE BAHNBRECHENDE ACCUTOX®-TECHNOLOGIE ZUR KREBSBEKÄMPFUNG ABDECKT
Vancouver, British Columbia (Kanada), den 4. März 2024 – Defence Therapeutics Inc. (......
Themefolio
Profiler
Peergroup
© Newsfile
04.03.2024
DTC
LISTED
CSE
Defence Therapeutics Awarded Broad U.S. Patent Covering Its Pioneering Cancer-Killing AccuTOX(R) Technology
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the granting of US patent no. 11,890,350 ('350) by the...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.03.2024
DTC
LISTED
CSE
DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY
News Preview
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY
Vancouver, BC, Canada, March 4th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceu......
Themefolio
Profiler
Peergroup
© Newsfile
01.03.2024
DTC
LISTED
CSE
Defence Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 29, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology, is pleased to announce the publication of a peer-reviewed study on the anticancer properties of...
Themefolio
Profiler
Peergroup
© Newsfile
31.01.2024
DTC
LISTED
CSE
Defence Therapeutics Completes 1st Tranche of Financing
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology, announces the closing of the 1st tranche of its previously announced non-brokered private pl...
Themefolio
Profiler
Peergroup
© Newsfile
20.01.2024
DTC
LISTED
CSE
Defence Financing
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology announces, further to its news release on January 12, 2024, an amendment on the financing. Th...
Themefolio
Profiler
Peergroup
© Newsfile
13.01.2024
DTC
LISTED
CSE
Defence Begins Trading on the OTCQB and Arranges Financing
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 12, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that it arranges a financing, and its common shares have been upgraded to...
Themefolio
Profiler
Peergroup
© EQS Newswire
10.01.2024
DTC
LISTED
CSE
ACCUTOX® VON DEFENCE HEMMT WACHSTUM VON LUNGENKREBS
News Preview
_________________________________________________________________
CSE: DTC Börse Frankfurt: DTC USOTC: DTCFF PRESSEMITTEILUNG
ACCUTOX® VON DEFENCE HEMMT WACHSTUM VON LUNGENKREBS
Vancouver, British Columbia, Kanada, den 10. Januar 2024 – Defence Therapeutics Inc. („Defence“ oder das „Unternehmen“), (CSE: DTC, OTCQB: DTCFF, Börse Frankfur......
Themefolio
Profiler
Peergroup
© Newsfile
10.01.2024
DTC
LISTED
CSE
Defence's AccuTOX(R) Impairs Lung Cancer Growth
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that it successfully tested a new formulation of its ACCUM-002TM Dime...
Themefolio
Profiler
Peergroup
© EQS Newswire
10.01.2024
DTC
LISTED
CSE
DEFENCE’S ACCUTOX® IMPAIRS LUNG CANCER GROWTH
News Preview
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE’S ACCUTOX® IMPAIRS LUNG CANCER GROWTH
Vancouver, BC, Canada, January 10th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), one of the leading Canadian biotechno......
Themefolio
Profiler
Peergroup
© Newsfile
12.12.2023
DTC
LISTED
CSE
RETRANSMISSION: Defence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R)
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that the U.S. FDA issued a "Study May Proceed", this clears its Investi...
Themefolio
Profiler
Peergroup
© Newsfile
11.12.2023
DTC
LISTED
CSE
Defence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R)
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 11, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that the U.S. FDA has cleared today "Study May Proceed" its Investigati...
Themefolio
Profiler
Peergroup
© Newsfile
14.11.2023
DTC
LISTED
CSE
Defence's Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 14, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that it has successfully submitted on November 9, 2023 an Investigatio...
Themefolio
Profiler
Peergroup
© Newsfile
07.11.2023
DTC
LISTED
CSE
Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 7, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing cutting-edge vaccines, therapeutics, and drug delivery technologies against cancer and other diseases, is pleased to announce th...
Themefolio
Profiler
Peergroup
© Newsfile
25.10.2023
DTC
LISTED
CSE
Defence's AccuTOX(R) And Antigen Cross-Presentation: Discovery Leads Towards the Development of a Groundbreaking Platform
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 25, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a leading Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the discovery of...
Themefolio
Profiler
Peergroup
© Newsfile
18.10.2023
DTC
LISTED
CSE
Defence's Novel Accutox(TM) Continues to Surprise on Results Against Cancer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 18, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that the excitement around AccuTOXTM...
Themefolio
Profiler
Peergroup
© Newsfile
17.10.2023
DTC
LISTED
CSE
Defence's Delivery of Encapsulated AccuTOX(TM)-Chitosan Nanoparticles Triggers Complete Tumor Regression in Animals with Pre-Established Solid Lymphoma
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 17, 2023) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that systemic administration of novel AccuTOXTM-chitosan encapsul...
Themefolio
Profiler
Peergroup
© Newsfile
10.10.2023
DTC
LISTED
CSE
Defence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer Science
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company developing various products for the immune-oncology vaccines and drug delivery technologies, is pleased to announce the publication of a peer-reviewed study on the...
Themefolio
Profiler
Peergroup
© Newsfile
07.10.2023
DTC
LISTED
CSE
Defence to Present Three of Its Leading Products at the Upcoming Festival of Biologics in Basel, Switzerland
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce its participation to the upcoming Fes...
Themefolio
Profiler
Peergroup
© Newsfile
25.09.2023
DTC
LISTED
CSE
Defence's Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 25, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that its encapsulation strategy us...
Themefolio
Profiler
Peergroup
© Newsfile
22.09.2023
DTC
LISTED
CSE
Defence to Collaborate with Native Ads for Marketing Campaign
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 22, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce it has entered into a servic...
Themefolio
Profiler
Peergroup
© Newsfile
12.09.2023
DTC
LISTED
CSE
Defence's Broad and Versatile Accum(R) Technology Platform Focus on Cancer Therapeutics
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 12, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies, is pleased to announce its continuation to bringing innovative strategies aimed at targeting various indications related to immune-o...
Themefolio
Profiler
Peergroup
© Newsfile
05.09.2023
DTC
LISTED
CSE
Defence's Innovative Therapeutics Featured on Viewpoint with Dennis Quaid
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company") a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce that Viewpoint, the educational television show distri...
Themefolio
Profiler
Peergroup
© Newsfile
18.07.2023
DTC
LISTED
CSE
Defence Successfully Completes the First Milestone of Its Collaboration Agreement with Orano
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 18, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company") is pleased to announce that it has successfully reached the first milestone established in the Collaboration Agreement with Orano Support SAS on behalf of Orano SA ("Orano"), a world-renowned...
Themefolio
Profiler
Peergroup
© Newsfile
05.07.2023
DTC
LISTED
CSE
RETRANSMISSION: Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthroughs in Biotechnology
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 5, 2023) - Defence Therapeutics Inc. ("Defence" or the "Company") a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce its collaboration with Viewpoint with Dennis Quaid. This exciting partnership aims to explore break...
Themefolio
Profiler
Peergroup
© Newsfile
04.07.2023
DTC
LISTED
CSE
Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthroughs in Biotechnology
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 4, 2023) - Defence Therapeutics Inc. ("Defence" or the "Company") a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce its collaboration with Viewpoint with Dennis Quaid. This exciting partnership aims...
Themefolio
Profiler
Peergroup
© Newsfile
28.06.2023
DTC
LISTED
CSE
Defence Patent Portfolio at the Forefront of Success
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 28, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company") is a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies. Sitting at the core of its innovative technologies is the proprietary Accum&#...
Themefolio
Profiler
Peergroup
© Newsfile
20.06.2023
DTC
LISTED
CSE
Defence's Proprietary Accum(TM) Technology for Delivery of CRISPR/Cas Genome-Editing Complexes Patent Application Published
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the publication of its new international (PCT) patent ap...
Themefolio
Profiler
Peergroup
© Newsfile
16.06.2023
DTC
LISTED
CSE
Defence Manufacturing of AccuTox(TM) CGMP Final Drug Product Optimization for Its Phase I Clinical Trial at City of Hope
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it reached the final stages of its...
Themefolio
Profiler
Peergroup
© Newsfile
06.06.2023
DTC
LISTED
CSE
Defence Begins Testing Its Arm Vaccine Against Pancreatic Cancer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it mandated Transbiotech Biote...
Themefolio
Profiler
Peergroup
© Newsfile
26.05.2023
DTC
LISTED
CSE
Defence Announces Additional and Final Exercises of Warrants for Gross Proceeds of Over $2.3 Million
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that, in addition to the previously anno...
Themefolio
Profiler
Peergroup
© Newsfile
24.05.2023
DTC
LISTED
CSE
Breakthrough Results: Defence's Arm Vaccine Cured 100% of Animals with Pre-Established Lymphoma
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 24, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the successful completion of a pre-clinic...
Themefolio
Profiler
Peergroup
© Newsfile
10.05.2023
DTC
LISTED
CSE
BTV Investor Alert - Defence Therapeutics: Developing Immune-Related Therapies for Cancer Treatment
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) - Defence Therapeutics is a Canadian biotech company that develops immune-related cancer therapies with proprietary technology. With three clinical trials scheduled by year-end, the company offers growth potential for investors. Def...
Themefolio
Profiler
Peergroup
© Newsfile
02.05.2023
DTC
LISTED
CSE
Defence's Successful AccuTOX(TM) Pre-Clinical Efficacy Study Complete Ready For Phase I IND Filing
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 2, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the successful completion of all required...
Themefolio
Profiler
Peergroup
© Newsfile
27.04.2023
DTC
LISTED
CSE
USPTO Grants Trademark Registration for Defence Therapeutics(R)
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2023) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted registration...
Themefolio
Profiler
Peergroup
© Newsfile
24.04.2023
DTC
LISTED
CSE
Defence Granted US Patent with Broad Coverage on Accum(TM)-based Vaccine Enhancer Platform Technology
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugates ("ADCs"), is pleased to announce the is...
Themefolio
Profiler
Peergroup
© Newsfile
17.04.2023
DTC
LISTED
CSE
Defence's Novel Accum(TM)-mRNA Vaccine Now Administered for Testing on Cancer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 17, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that it commenced comparing the therap...
Themefolio
Profiler
Peergroup
© Newsfile
11.04.2023
DTC
LISTED
CSE
RETRANSMISSION: Defence Breakthrough: Successfully Engineered Accum(TM)-mRNA Vaccine Creating a New Vaccine Platform. The in vivo Accum(TM)-mRNA Cancer Vaccine Program Begins
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 11, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that it successfully established a st...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
